Abstract
We report a patient with chemotherapy-naïve advanced pancreatic cancer having multiple liver metastases which dramatically responded to S-1, an oral fluoropyrimidine. The patient was enrolled in the "Late Phase II Clinical Study of S-1 in Patients with Advanced Pancreatic Cancer." Anti-tumor efficacy after the first four courses of S-1 monotherapy was confirmed to be partial response (PR) in overall response by Response Evaluation Criteria in Solid Tumors (RECIST). Grade 3 neutropenia was observed, but no other severe toxicities were noted. On the basis of the results of the late phase II clinical study, S-1 is a promising agent for systemic chemotherapy against advanced pancreatic cancers because of its excellent efficacy, high tolerability, and convenient route of oral administration.
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Adenocarcinoma / secondary
-
Antimetabolites, Antineoplastic / administration & dosage*
-
Antimetabolites, Antineoplastic / adverse effects
-
Clinical Trials, Phase II as Topic
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives
-
Drug Administration Schedule
-
Drug Combinations
-
Female
-
Gemcitabine
-
Humans
-
Liver Neoplasms / diagnostic imaging
-
Liver Neoplasms / secondary*
-
Middle Aged
-
Neutropenia / chemically induced
-
Oxonic Acid / administration & dosage*
-
Oxonic Acid / adverse effects
-
Pancreatic Neoplasms / drug therapy*
-
Pancreatic Neoplasms / pathology
-
Tegafur / administration & dosage*
-
Tegafur / adverse effects
-
Tomography, X-Ray Computed
Substances
-
Antimetabolites, Antineoplastic
-
Drug Combinations
-
Deoxycytidine
-
S 1 (combination)
-
Tegafur
-
Oxonic Acid
-
Gemcitabine